StreetInsider.com News Articles

Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026

Mon, 19 Oct 2026 16:01:00 -0400

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2026 after market close on Thursday, November 12, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2026.

Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique

Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026

Mon, 19 Oct 2026 16:01:00 -0400

Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique

HeartFlow (HTFL) PT Raised to $56 at Baird

Thu, 15 Oct 2026 07:22:15 -0400

Baird analyst David Rescott raised the price target on HeartFlow (NASDAQ: HTFL) to $56.00 (from $45.00) while maintaining a Outperform rating.

Form 4 Heartflow, Inc. For: Oct 12 Filed by: Farquhar John C.M.

Wed, 14 Oct 2026 18:05:00 -0400

si-local-file:///var/storage/secattach/20261014/27188073.html

Form 144 Heartflow, Inc. Filed by: Farquhar John C.M.

Tue, 13 Oct 2026 08:22:00 -0400

si-local-file:///var/storage/secattach/20261013/27177698.html

HeartFlow (HTFL) PT Raised to $56 at Canaccord

Tue, 22 Sep 2026 04:57:40 -0400

Canaccord analyst William Plovanic raised the price target on HeartFlow (NASDAQ: HTFL) to $56.00 (from $45.00) while maintaining a Buy rating.

The analyst comments "Bottom line: We heard you! Based on investor feedback from our last survey, we doubled our sample size to 50 active physicians who use plaque analysis in the fourth edition of our plaque survey to gain a better understanding of the dynamics of the fast-growing plaque field. Further, we focused on physicians who truly order and use plaque analysis by limiting our pool to general cardiologists, imaging-focused cardiologists, and radiologists, and we removed interventional cardiologists as they

HeartFlow (HTFL) PT Raised to $56 at Canaccord

Tue, 22 Sep 2026 04:57:40 -0400

Canaccord analyst William Plovanic raised the price target on HeartFlow (NASDAQ: HTFL) to $56.00 (from $45.00) while maintaining a Buy rating.

Form 4 Heartflow, Inc. For: Sep 18 Filed by: Rogers Campbell

Mon, 21 Sep 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260921/27086259.html

Form 4 Heartflow, Inc. For: Sep 17 Filed by: Verghese Vikram

Fri, 18 Sep 2026 20:47:00 -0400

si-local-file:///var/storage/secattach/20260918/27081573.html

Form 144 Heartflow, Inc. Filed by: Verghese Vikram

Fri, 18 Sep 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260918/27080781.html

Form 144 Heartflow, Inc. Filed by: Rogers Campbell

Fri, 18 Sep 2026 10:12:00 -0400

si-local-file:///var/storage/secattach/20260918/27079061.html

Form 144 Heartflow, Inc. Filed by: Rogers Campbell

Fri, 18 Sep 2026 09:57:00 -0400

si-local-file:///var/storage/secattach/20260918/27078974.html

Form 144 Heartflow, Inc. Filed by: Verghese Vikram

Thu, 17 Sep 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260917/27076391.html

Form 4 Heartflow, Inc. For: Sep 11 Filed by: Verghese Vikram

Tue, 15 Sep 2026 19:45:00 -0400

si-local-file:///var/storage/secattach/20260915/27066173.html

Form 144 Heartflow, Inc. Filed by: Verghese Vikram

Tue, 15 Sep 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260915/27065396.html

Form 4 Heartflow, Inc. For: Sep 10 Filed by: Farquhar John C.M.

Mon, 14 Sep 2026 18:42:00 -0400

si-local-file:///var/storage/secattach/20260914/27059637.html

Form 144 Heartflow, Inc. Filed by: Verghese Vikram

Mon, 14 Sep 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260914/27058628.html

Form 144 Heartflow, Inc. Filed by: Farquhar John C.M.

Fri, 11 Sep 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260911/27053482.html

Form 144 Heartflow, Inc. Filed by: Verghese Vikram

Fri, 11 Sep 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260911/27053289.html

Form 4 Heartflow, Inc. For: Sep 08 Filed by: Verghese Vikram

Thu, 10 Sep 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260910/27049478.html

Form 144 Heartflow, Inc. Filed by: Farquhar John C.M.

Thu, 10 Sep 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260910/27048901.html

UBS Assumes HeartFlow (HTFL) at Neutral

Wed, 09 Sep 2026 06:08:44 -0400

UBS analyst Douglas Schenkel assumes coverage on HeartFlow (NASDAQ: HTFL) with a Neutral rating and a price target of $55.00.

For an analyst ratings summary and ratings history on HeartFlow click here. For more ratings news on HeartFlow click here.

Shares of HeartFlow closed at $47.75 yesterday.

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

Fri, 28 Aug 2026 02:48:00 -0400

SAN FRANCISCO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced late-breaking one-year results from an independent randomized clinical trial proving the Heartflow FFRCT Analysis safely and significantly reduced unnecessary invasive heart procedures by 44% (p < 0.001).

Presented as Late-Breaking Science at the European Society of Cardiology (ESC) Congress 2026, FUSION trial, funded by the Dutch National Health Care Institute, demonstrates that standard coronary computed tomography angiography (CCTA) alone drives overutilization of invasive catheterizations.1 By adding Heartflow FFRCT Analysis to

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

Fri, 28 Aug 2026 02:48:00 -0400

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

Fri, 28 Aug 2026 02:48:00 -0400